You are here

Ipsen

FDA Decisions 2023: Sandoz, Gilead Sciences and More

FDA Decisions 2023: Sandoz, Gilead Sciences and More

BioSpace

Gilead Sciences

Revance Therapeutics

Delcath Systems

Galera Therapeutics

Flag link:

Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer

Exelixis and Ipsen to seek approval for Cabometyx in prostate cancer

Clinical Trials Arena

prostate cancer

Flag link:

FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease

FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease

BioSpace

fibrodysplasia ossificans progressiva

Flag link:

FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

FDA Action Alert: Ipsen, Revance, Neurocrine and Regeneron

BioSpace

Revance Therapeutics

fibrodysplasia ossificans progressiva

cervical dystonia

Huntington's disease

Flag link:

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

5 Highly Anticipated FDA Decisions for Rare Diseases Coming This Year

BioSpace

fibrodysplasia ossificans progressiva

Santhera Pharmaceuticals

Flag link:

Ipsen and Genfit to file for EMA and FDA approval for elafibranor

Ipsen and Genfit to file for EMA and FDA approval for elafibranor

Clinical Trials Arena

primary biliary cholangitis

Flag link:

FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP

FDA Advisory Committee Recommends Ipsen's Palovarotene as an Effective and Safe Treatment for FOP

Globe Newswire

fibrodysplasia ossificans progressiva

Flag link:

FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm

FDA Warms Up to Ipsen’s Post-Hoc Analysis for Rare Disease Drug Ahead of Adcomm

BioSpace

fibrodysplasia ossificans progressiva

Flag link:

After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use

After Albireo buyout, Ipsen's Bylvay picks up new FDA-approved use

Fierce Pharma

Flag link:

Pfizer's fortunes overshadow first-quarter dealmaking

Pfizer's fortunes overshadow first-quarter dealmaking

EP Vantage

Flag link:

FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on

FDA agrees to give Ipsen's rare disease drug another look as palovarotene saga rumbles on

Fierce Biotech

fibrodysplasia ossificans progressiva

Flag link:

Ipsen reports positive data from pancreatic ductal adenocarcinoma trial

Ipsen reports positive data from pancreatic ductal adenocarcinoma trial

Clinical Trials Arena

metastatic pancreatic cancer

pancreatic cancer

clinical trials

Flag link:

Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial

Irlab's shares plummet 60% after Ipsen-partnered Parkinson's drug flunks phase 2 trial

Fierce Biotech

clinical trials

Parkinson's Disease

Flag link:

Biopharma’s bolt-on bonanza is set to continue

Biopharma’s bolt-on bonanza is set to continue

EP Vantage

Bristol Myers Squibb

Flag link:

Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting

Trio of biotech buyouts jumpstarts J.P. Morgan healthcare meeting

BioPharma Dive

Chiesi Farmaceutici

Flag link:

Ipsen's rare disease candidate rejected after mounting setbacks, delays

Ipsen's rare disease candidate rejected after mounting setbacks, delays

Fierce Biotech

Flag link:

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

AbbVie, Ipsen exit R&D deals to cap off lousy year for Exicure

Fierce Biotech

Flag link:

Go or no go? Mirati heads to the FDA

Go or no go? Mirati heads to the FDA

EP Vantage

Mirati Therapeutics

Gilead Sciences

Coherus Biosciences

TG Therapeutics

Flag link:

Pages